Centessa Pharmaceuticals (CNTA) stock surged over 46% pre-market after Eli Lilly agreed to acquire it. The deal offers $38 per share in cash, potentially rising to $47 with a contingent value right. The $6.3 billion acquisition aims to expand Eli Lilly's footprint in neuroscience and sleep disorder treatments, aligning with its growth strategy.